INTRODUCTION
induces the release of Ca2+ from the dense-tubular system [1] , whereas diacylglycerol activates protein kinase C (PKC), a serine/threonine kinase [2] . Subsequently PKC stimulates the Na+/H+ exchanger, an antiport in the plasma membrane that regulates the cytosolic pH [3] , initiates Ca2+ sequestration [4] , induces the exposure of binding sites for adhesive proteins on the glycoprotein IIB/IIIA complex (GPIIB/IIIA) [5, 6] , facilitates InsP3 degradation [7] , and affects the interaction of several GTPbinding proteins with their target enzymes [8, 9] .
Adrenaline is an agonist with unique properties. Initially, it was thought to activate platelets in a synergistic action with trace amounts of other agonists, but recently it has become apparent that adrenaline alone can activate platelets [10] . It induces aggregation, without appreciable activation of PLC [11] and PKC [1 1, 12] , and fails to change the cytosolic Ca2+ concentration, as detected with Quin-2 or Fura-2 fluorescence [13] . On the other hand, adrenaline activates phospholipase A2 (PLA2) via a probably pertussis-toxin-sensitive GTP-binding protein [14, 15] and inhibits adenylate cyclase via the inhibitory GTP-binding protein, G, [9] . Activation of PLA2 results in rapid liberation of arachi-81072 + 7293 (n = 3) binding sites for 1251-fibrinogen per platelet, and (iv) irreversible aggregation. These responses occurred without changes in cytosolic [Ca2+] , secretion of dense-granule contents and enhanced phosphoinositide metabolism, and were not affected by inhibition of thromboxane A2 generation (30 ,#M indomethacin). The a2A-adrenergic-receptor antagonists oxymetazoline (500 ,uM) and yohimbine (1 mM) completely abolished DIDS-induced responses. Inhibition of PKC (1 ,sM staurosporine) prevented phosphorylation of the 47 kDa protein, the increase in Na+/H+ exchange and exposure of fibrinogen-binding sites. Thus our present data suggest that activation of PKC is an early event in DIDS-induced platelet activation via the a2A-adrenergic receptor, which precedes any of the other known signal-transducing sequences.
donic acid and formation of prostaglandin endoperoxides and thromboxane A2 [11, 16] .
In their studies on pH regulation in platelets, Banga et al. [17] observed that an early step in adrenaline-induced signal processing is activation of the Na+/H+ exchanger. The resulting alkalinization preceded activation of PLA2 and further signal processing, suggesting that the Na+/H+ exchanger is closely coupled to a2A-adrenergic receptors (a2A-AR) or may even form an intrinsic property of these receptors. This would be in contrast with activation of the Na+/H+ exchanger in platelets stimulated with a-thrombin, platelet-activating factor ('PAF') or ADP, which appears to be controlled by cytosolic Ca2' and PKC [3, 18] .
In the present study, we found that 4,4'-di-isothiocyanatostilbene-2,2'-disulphonic acid (DIDS), which is commonly used to inhibit the Cl-/HCO3-exchanger, strongly activated the a2A-AR, in accordance with an earlier observation by Periyasamy and Somani [19] . This property provided a tool to characterize cc2A-AR-mediated signal processing in platelets, especially with respect to the role of Na+/H+ exchange and its possible control by PKC.
EXPERIMENTAL Materials
2,7-Biscarboxyethyl-5(6)-carboxyfluorescein tetra-acetoxymethyl ester (BCECF-AM) was obtained from Calbiochem (Frankfurt, Germany). Staurosporine was from Boehringer Abbreviations used: DIDS, 4,4'-di-isothiocyanatostilbene-2,2'-disulphonic acid; SITS, 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulphonic acid; DTSSP, 3,3'-dithiobis(sulphosuccinimidyl)propionate; AR, adrenergic receptor; H7, 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine; EIPA, ethyliso- propylamlloride; PRP, platelet-rich plasma; PKC, protein kinase C; GPIIB/IIIA, glycoprotein llB/lIlA complex; PLC, phospholipase C; PLD, phospholipase D; PLA2, phospholipase A2; PA, phosphatidic acid; BCECF-AM, 2,7-biscarboxyethyl-5(6)-carboxyfluGrescein tetra-acetoxymethyl ester; cAMP, cyclic AMP; cGMP, cyclic GMP; dbcAMP: dibutyryl cAMP; PGI2, prostacyclin; pH,, intracellular pH; GRGDS: Gly-Arg-Gly-Asp-Ser.
* To whom correspondence should be addressed.
(Mannheim, Germany). Sepharose 2B was from Pharmacia (Uppsala, Sweden). 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulphonic acid (SITS) and yohimbine were from Aldrich (Brussels, Belgium). a-Thrombin, nigericin, oxymetazoline, DIDS, indomethacin, (-)-adrenaline, dibutyryl cyclic AMP (dbcAMP), H7 [1-(5- 
Platelet isolation
Freshly drawn venous blood from healthy volunteers (with informed consent) was collected into trisodium citrate (0.1 vol. of 130 mM). The donors claimed not to have taken any medication during the previous 10 days. Platelets were isolated by either gel-filtration or centrifugation (as described below). For the preparation of gel-filtered platelets, citrated blood was centrifuged (200 g, 10 min, 22°C), and the platelet-rich plasma (PRP) was placed on a Sepharose 2B column equilibrated in Ca2+-free Tyrode's solution (137 mM NaCl, 2.68 mM KCI, 0.42 mM NaH2PO4, 1.7 mM MgCl2, 11.9 mM NaHCO3, pH 7.25) containing 0.1 0% glucose and 0.2 % BSA.
Measurement of intracellular pH (pH,)
This was done with the fluorescent pHi-sensitive indicator BCECF-AM. PRP was acidified to pH 6.5 with 6 vol. of ACD (2.5 g of trisodium citrate, 1.5 g of citric acid and 2.0 g of D-glucose in 100 ml of water), and platelets were isolated by centrifugation (700 g, 15 min, 22 C). Subsequently, the cells were resuspended in 1 ml of Hepes/Tyrode buffer (145 mM NaCl, 5 mM KCI, 0.5 mM Na2HPO4, 1 mM MgSO4, 10 mM Hepes), pH 6.5, containing 0.1 % (w/v) glucose and 0.2 % (w/v) gelatin. The platelets were incubated with BCECF-AM (3 ,uM) in the absence or presence of indomethacin (30,M) [20] .
Measurement of PKC activity
Platelets were labelled with 3.7 MBq of carrier-free [32P]P1/ml of acidified PRP (pH 6.5), with or without a simultaneous incubation with indomethacin (30 ,uM) for 1 h at 37 'C. The platelets were isolated by centrifugation (700 g, 15 min, 22°C) and were resuspended in Hepes/Tyrode buffer (pH 7.2), resulting in a final platelet count of (150-200) x 103/,ul. Labelled platelets were stimulated with 20 ,uM DIDS or 1 unit/ml a-thrombin at 37 'C, and samples were collected at the times indicated in the Results section, transferred into 0.5 vol. of3-times-concentrated Laemmli sample buffer and heated for 2 min at 100 'C before electrophoresis. Proteins were separated by electrophoresis through a 11 %-polyacrylamide gel, as described by Laemmli [21] . Gels were stained with Coomassie Brilliant Blue, and the distribution of radioactivity was determined by autoradiography of dried gels on Kodak Royal X-Omat film. For determination of the radioactivity of the 47 kDa protein, the specific area was cut out of the dried gels and heated for 2 h at 80 'C in 30 % H202. The radioactivity was determined by liquid-scintillation counting. In control experiments no difference in phosphorylation patterns could be detected between centrifuged and gel-filtered platelets (G. van Willigen, unpublished work).
Data are expressed as percentage of the maximal phosphorylation induced by 1 unit/ml a-thrombin, to minimize the variation in 47 kDa-protein radioactivity in resting platelets from different donors.
Fibrinogen-binding assay
Gel-filtered platelets [(200-300) x 103 platelets/,ll] were stimulated with a-thrombin (1 unit/ml) (30 nM D-phenylalanyl-Lprolyl-L-arginylchloromethane was added 3 min after stimulation to prevent coagulation), or with DIDS (20 ,uM) in the presence of 125I-labelled fibrinogen (1 ,uM) at 22 'C and 37 'C. Fibrinogen was purified and iodinated as described elsewhere [22] . At the times indicated in the Results section, a sample (in triplicate) of 200 #u1 was drawn and layered on 100 ,ul of 25 % (w/v) sucrose in Ca2+-free Tyrode's solution in micro-sedimentation tubes (Sarstedt, Vienna, Austria) and centrifuged (10000 g, O min, 22°C), in a Beckman Microfuge E. The pellet and supernatant were separated and counted for radioactivity in a y-radiation counter. The number of molecules of 125I-fibrinogen bound per platelet was calculated from the radioactivity in the pellet fraction compared with the total radioactivity in pellet plus supernatant. The data are expressed as means + S.D. (n = 3) and corrected for non-specific binding, defined as the binding of 1251-fibrinogen to unstimulated platelets. Details of these procedures have been described elsewhere [23] .
Platelet aggregation, single platelet disappearance and ATP secretion Gel-filtered platelets, treated with or without indomethacin (30 ,uM) for 30 min at 22 'C, were prepared as described above. The platelet count was adjusted with Ca2+-free Tyrode's solution to 200 x 103 cells/1I. After addition of fibrinogen (1 1sM) the agonists were added and aggregation was measured by two techniques; first, by measuring the disappearance of single platelets [24] , and second by measuring the change in light transmission in the aggregometer (designated as optical aggregation). For the first-mentioned procedure, samples were collected at 2 min after addition of the agonist and immediately fixed with 9 vol. of ice-cold 0.9 % NaCl/0.5 % (v/v) glutaraldehyde. The platelets were counted in a Platelet Analyzer 810 (Baker Instruments, Allentown, PA, U.S.A.) with apertures set at 3.2 and 16,um3. Optical aggregation was measured in a Chronolog lumiaggregometer at 37°C and a stirring speed of 900 rev./min. Simultanously, the secretion of ATP was measured by using the Chronology firefly reagent.
Secretion of hydroxy[14C]tryptamine
Platelets were loaded with hydroxy[14C]tryptamine (1 ,uM) 
Measurement of Ptdins(4,5)P2 and phosphatidic acid (PA)
Changes in PtdInsPF and PA were measured by a modified procedure described by Jolles et al. [25] for rat brain cells. In short, platelets were labelled with [32] Pi and isolated by centrifugation as described above under 'Measurement of PKC activity'. Platelets were stimulated with the various agonists, and the reactions were terminated at different time points by adding 2 ml of chloroform/methanol/13 M HCI (100:50:1, by vol.; 0°C). The lipids were extracted as described by Bligh and Dyer [26] . Phospholipids were separated by high-performance t.l.c., and the radioactivity was determined by autoradiography of the plate on Kodak Royal X-Omat film. The spots were scraped off and counted for 32P by liquid-scintillation counting. The 32p content is expressed as a percentage of that of unstimulated platelets.
Presentation of data
Data are expressed as means+S.D. unless indicated otherwise. Statistical significances were determined by Student's t test, and were considered significant at P < 0.05. All experiments were performed with at least three different platelet preparations (in duplicate or triplicate per donor). DIDS is known as an inhibitor of the Cl-/HCO3 exchanger, which in many cell types contributes to pHi control [29, 30] .
In addition, DIDS induces cross-linking of membrane proteins in human platelets [31] . Therefore, control experiments were performed to ascertain that DIDS-induced Na+/H+ exchange was exclusively due to activation of the a2A-AR. First, the experiments were repeated in the presence of 30 mM HCO3-to enable the operation of the Cl-/HCO3 exchanger, but this treatment failed to affect the changes in pHi induced by DIDS or a-thrombin (results not shown). Second, platelets were treated with SITS (20 ,M), like DIDS an inhibitor of Cl-/HCO3-exchange and possessing a structure similar to DIDS, apart from lacking one of the two isothiocyanato groups [31] . SITS failed to affect the pH, at even a 10-fold higher concentration than DIDS ( Figure   le ). The property of DIDS to cross-link platelet membrane glycoproteins was mimicked by addition of DTSSP (20 ,uM) , which also cross-links platelet membrane surface proteins [32] , but again no change in pHi was observed (Figure 1f ). In Table 1 the pHi responses upon addition of DIDS and a-thrombin as well as the different control studies are summarized. Taken together, these findings indicate that DIDS modulates Na+/H+ exchange in platelets via a mechanism that is apparently not affected by inhibition of Cl-/HCO3-exchange or cross-linking of membrane proteins. Noteworthy is the observation that the sensitivity of the platelets from different donors to DIDS appeared to fall in two the DIDS-induced activation of the Na+/H+ exchanger was not affected by either fibrinogen or GRGDS and fibrinogen (Table  1) . Thus the activation of the Na+/H+ exchanger by DIDS appears to result from activation of PKC without apparent involvement of fibrinogen binding. Figure 2 , addition of DIDS (20 FM) triggered a 3.5-4-fold increase in the phosphorylation of the 47 kDa protein, the major substrate of PKC in platelets. This increase was preceded by a lag phase of about 10 s, which fell in the period in which the pHi decreased (Figure la) . The 47 kDa-protein phosphorylation was transient and had returned to levels found in resting platelets after 5 min. A similar rise in 47-kDa-protein phosphorylation was found upon stimulation with a-thrombin (1 unit/ml), but here the rise was immediate and the phosphorylation remained high for at least 5 min.
DIDS-induced activation ot PKC As illustrated in
To investigate whether the DIDS-induced activation of PKC was an a2A-AR-mediated event, the platelets were preincubated with oxymetazoline (500,uM). This treatment completely inhibited the phosphorylation ofthe 47 kDa protein such in parallel with the abolishment of increased Na+/H+ exchange. No activation of PKC was observe when DIDS was replaced by SITS (20 F,M; Figure 2 ) or DTSSP (20 FM), which is in concert with the effect of these agents on the Na+/H+ exchanger ( Figure 1 ).
To identify the pathways that play a role in the coupling of the a2A'AR to PKC, platelets were pretreated with indomethacin (30 FM), 8 '-bromo-cGMP (1.5 mM) or dbcAMP (2.5 mM). Indomethacin failed to affect the 47 kDa-protein phosphorylation patterns triggered by DIDS (results not shown), but pretreatment with 8'-bromo-cGMP (1.5 mM) prolonged the lag phase to about 20 s. Thereafter, the phosphorylation proceeded undisturbed (Figure 2) . Elevation of cAMP by dbcAMP (2.5 mM) completely blocked DIDS-induced 47 kDa-protein phosphorylation. As expected, no increase in phosphorylation of the 47 kDa protein was seen in platelets that had been treated with stauro- sporine (1 1aM 
DIDS-induced aggregation
When gel-filtered platelets were stimulated with oc-thrombin (1 unit/ml), a rapid irreversible aggregation was observed (Figure 5a ). Addition of DIDS (20 ,uM) in the presence of 1 ,uM fibrinogen also induced platelet aggregation ( Figure Sb) . The DIDS-induced aggregation was not preceded by shape change, which is also observed after adrenaline-induced aggregation [11] . Preincubation with indomethacin (30 ,M; 30 min; 37 C) did not affect DIDS-induced aggregation (Figure 5c ), but preincubation with 8'-bromo-cGMP (1.5 mM) decreased the aggregation velocity (Figure 5d ). When platelets were preincubated with oxymetazoline (500 ,uM; Figure Figure 5, insert) , which revealed that only 2.8 + 0.1 % of the total secretable 5-hydroxytryptamine was released after 5 min stimulation with DIDS. Also, in studies in the presence of apyrase, a scavenger of ADP, no inhibition of DIDS-induced aggregation was found, indicating that ADP was not released and did not contribute to platelet activation upon stimulation by DIDS. Figure 6 illustrates in more detail the inhibition by oxymetazoline of DIDS-induced aggregation, measured by the disappearance of single platelets at 2 min after stimulation. Oxymetazoline dose-dependently inhibited DIDS-induced aggregation, showing an EC50 of about 70 MM and more than 90 % inhibition at 500 MM. Yohimbine was a less potent inhibitor than oxymetazoline, with an EC50 of about 700 MM and complete inhibition at 1 mM. These values are 10-100 times those for inhibition of adrenaline-induced single-platelet disappearance.
DISCUSSION
The results presented in this paper show that DIDS activates the Na+/H+ exchanger, thereby inducing an increase in pHi. This action has all the properties of a specific reaction involving the M2A-AR, since it is abolished by a2A-AR antagonists and appears to be independent of two other properties of DIDS, that are the inhibition of Cl-/HCO3-exchange and cross-linking of membrane glycoproteins. Both SITS, which is equally effective as DIDS as a blocker of Cl-/HC03-exchange, and DTSSP, which, similarly to DIDS, is a non-cell-permeant cross-linking reagent that spans 1.2 nm [31] , failed to activate the Na+/H+ exchanger.
Therefore DIDS appears a suitable tool with which to investigate signal processing via the a.2A-AR in platelets and possibly also in other cells.
The first question to address was whether the activation of the Na+/H+ exchanger was directly caused by the binding of DIDS to the a2A-AR or whether other cell signalling pathways were involved. Banga et al. [17] postulated that binding of adrenaline to a2A-AR on platelets directly activates the Na+/H+ exchanger and that activation ofPLA2 is a secondary event. Our observation that inhibition ofprostaglandin endoperoxides and thromboxane A2 formation fails to affect DIDS-induced pHi changes and subsequent responses is in line with this model. The lack of a specific inhibitor for PLC-mediated signal transduction made it difficult to evaluate whether activation of the Z2A-AR triggered the activation of PLC. When DIDS was added to platelets, only minor changes in 32P-labelled PtdIns(4,5)P2 and metabolites were observed, which disappeared completely after treatment with staurosporine. Thus the minor activation of PLC seen after stimulation with DIDS occurs secondary to activation of PKC. Also, Fura-2 fluorescence remained in the range of that for unstimulated cells, indicating that DIDS did not initiate Ca2+ mobilization. Pretreatment with 8'-bromo-cGMP, which directly raises the cGMP content in the cell [38] , partially inhibited the DIDS-induced alkalinization. We interpret these data as a direct effect of cGMP on the a2A-AR or on the mechanisms that couple this receptor to the Na+/H+ exchanger.
An alternative pathway for formation of diacylglycerol is via phospholipase D (PLD)-mediated liberation of PA, followed by a dephosphorylation step. This would provide a second mechanism for activation of PKC. The observation that activation of PLD is secondary to an increase in PLC activity [39] , and the fact that we failed to detect a major increase in [32P]PA in the present experiments (Figure 3 ), argue against a role of PLD in DIDSinduced platelet activation. DIDS-induced pHi changes were completely abolished by raising the level of cAMP. Wachtfogel et al. [40] have shown that an increase in cAMP in platelets leaves the number of a2A-AR and the Kd undisturbed in studies using [3H]yohimbine as a ligand. The binding of DIDS to the a2A-AR may therefore be equally insensitive to alterations in the cAMP concentration, and the inhibition of Na+/H+ exchange by cAMP must be due to interference with the mechanisms that control the Na+/H+ exchanger upon activation with DIDS.
Previous studies have demonstrated that direct activation of PKC with phorbol ester or l-oleoyl-2-acetylglycerol induced cytosolic alkalinization, due to activation of the Na+/H+ exchanger [41] . These findings indicate that phosphorylation of the Na+/H+ exchanger by PKC is an important mechanism for pHi control. Recently Pouyssegur and colleagues cloned the human Na+/H+ exchanger and found phosphorylation of the antiporter by growth factor and phorbol ester [42, 43] . Our present data indicate that the Na+/H+ exchanger in platelets is also regulated by a phosphorylation step. When platelets were preincubated with staurosporine, a widely used inhibitor of PKC, the DIDSinduced Na+/H+ exchange was completely inhibited. Although staurosporine has a number of side effects [44] [45] [46] [47] and others finding no interference [48] . We were repeatedly unable to show inhibition of 47 kDa-protein phosphorylation by dbcAMP (2.5 mM) in platelets stimulated with PMA (results not shown). We therefore propose that the sensitivity to cAMP and, possibly, to cGMP of the DIDS-induced PKC activation is related to a distinct step that mediates the interaction between the a2A-AR and PKC. By analogy with the studies on DIDS-induced Na+/H+ exchange, the changes in PKC activity were an a2A-AR-mediated event, since oxymetazoline completely inhibited the phosphorylation of the 47 kDa protein.
Previous studies have releaved a close correlation between the phosphorylation of the 47 kDa protein and the exposure of binding sites for fibrinogen on GPIIB/IIIA [5] . The present data show a similar relation when DIDS is the activating agent. Again, the binding of 1251-fibrinogen was completely prevented by oxymetazoline and yohimbine, confirming the participation of the a2A-AR. Preincubation with indomethacin had no effect, whereas 8'-bromo-cGMP induced a similar delay to that seen with measurements of pH, and 47 kDa-protein phosphorylation.
Not surprisingly, staurosporine inhibited all specific 1251-fibrinogen binding. Also an increase in the cAMP level (by dbcAMP or PGI2) completely inhibited the exposure of fibrinogen-binding sites induced by DIDS. This inhibition is also seen when platelets are stimulated with agonists such as ADP, a-thrombin and adrenaline [49] .
It is apparent that the platelet responses induced by DIDS and adrenaline have much in common. Both agonists activate platelets via the a2A-AR, resulting in the activation of the Na+/H+ exchanger [17] , independent of PLC [17] or changes in cytosolic Ca2+ content [11, 12] . They also induce fibrinogen binding and aggregation without shape change and secretion [12, 50] . A notable difference is the activation of PKC. Whereas adrenaline induces little or virtually no activation of PKC [51, 52] , the DIDS-induced PKC activation is comparable with that seen in athrombin-treated platelets. However, there is some evidence that adrenaline activates PKC in the presence of fibrinogen [17] and that it enhances PKC activity in the presence of the Ca2+ ionophore A23187 [52] or ADP [51] . The recent observation that adrenaline induces fibrinogen biding via a staurosporine-sensitive mechanism [5] also supports the concept that the a2A-AR is coupled to PKC.
Human platelets are a prototypic tissue for a2A-adrenergic receptors. The receptor consists of 430 amino acids and contains seven putative transmembrane spanning domains, thus placing this receptor in the family of G-protein-coupled receptors [53] . The different transmembrane domains serve in the binding of agonists and antagonists. The fourth and seventh domains are involved in the binding of adrenaline and noradrenaline [54, 55] , whereas the third and seventh take part in the binding of yohimbine [56, 57] . Oxymetazoline probably binds to other domains, since point mutations in the second and third transmembrane domains of the a2A-AR differently affect the binding of yohimbine and oxymetazoline [56] .
The affinity of a2A-adrenergic receptors for agonists as well as antagonists is regulated by Na+ ions, which bind to the second transmembrane domain. Mutation of aspartate-79 in this domain abolishes the Na+-sensitivity of agonists as well as antagonists [58] . Oxymetazoline probably binds to the Na+-binding site or to an adjacent region, since it contains an imidazole nucleus [59] .
DIDS may bind to the same site, since the Na+-sensitivity of [3H]yohimbine binding is completely abolished by 1 mM DIDS [19] . Thus differences in binding of yohimbine and oxymetazoline may explain why oxymetazoline is a much more potent antagonist of DIDS-induced Na+/H+ exchange and platelet aggregation than is yohimbine. The sesitivity of DIDS-induced platelet aggregation to oxymetazoline as well as to yohimbine is much lower that that of adrenaline-induced responses. Probably the difference in binding sites of these components affects the sensitivity to these antagonists. Thus, although both adrenaline and DIDS appear to activate platelets via the a2A-AR, their interaction with the receptor may show considerable differences.
